- cafead   Jul 31, 2024 at 10:22: AM
via FibroGen is radically restructuring its business, laying off 75% of its U.S. staff and stopping investment in its lead candidate in response to the failure of two late-phase pancreatic cancer clinical trials.
article source
article source